![Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast” | Business Wire Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast” | Business Wire](https://mms.businesswire.com/media/20190724005404/en/734567/23/3951103_Sage_Lock-up_Primary_BType_RGB_TM_%282%29+copy.jpg)
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast” | Business Wire
![Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care](https://investors.biogen.com/sites/g/files/knoqqb58286/themes/site/nir_pid1897/dist/images/banner1.jpg)
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care
Sage Therapeutics (SAGE) - price stock, stock chart, quote online, dividends, stock analysis, stock news, company profile | Finrange.com
![Sage Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation (NASDAQ:SAGE) | Seeking Alpha Sage Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation (NASDAQ:SAGE) | Seeking Alpha](https://static2.seekingalpha.com/uploads/sa_presentations/63/69063/slides/1.jpg?1620137990)